Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Amit Sanyal, MD: A Clinician’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement




Sep
09
Today In Oncology
ELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC
Prostate Cancer Higher Saturated Fat Intake May Be Linked to Worse Outcomes
Duane Mitchell Named Director of the UF Health Cancer Institute
Long-Course Chemoradiotherapy Shows Early Organ Preservation Advantage in Rectal Cancer
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo